Global Life Science Ventures — Investing in the life sciences

Global Life Science Ventures (GLSV) is a leading, independent venture capital fund focusing exclusively on the life sciences. GLSV is dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund may also invest in selected later stage companies, including buy-outs. For this purpose, GLSV provides finance, advice and access to expertise and networks. The group currently advises and manages funds totalling more than € 200 million. With offices in Germany and Switzerland, GLSV acts as one team with a global perspective.

Profile
Team
Investment Practice
Portfolio
FAQ
Download Area
News
Events
Contact Us
Text size

GLSV news

14.01.2010 Global Life Science Ventures: 2009 Review more...

13.02.2009 Global Life Science Ventures: 2008 highlights more...

22.04.2008 GLSV receives 2007 Dyodelta European Life Science Innovation Award "Investor of the Year Award" more...

14.04.2008 April 2008 Teil 20 der Serie: Köpfe der deutschsprachigen Private Equity-Szene, Hanns-Peter Wiese, Venture Capial Magazin 4/2008 more...

17.01.2008 GLSV leads investment in Action Pharma A/S more...

06.12.2007 GLSV invests in Pelikan Technologies more...

02.10.2007 Biotech Investment Barometer Reveals Continued Confidence in Sector
more...

11.05.2007 NeurogesX Launches IPO on NASDAQ more...

29.03.2007 GLSV co-leads Series E investment in Coapt Systems more...

20.12.2006 "10 years' investing in the life sciences" more...

More news

............................................................................................

Portfolio company news

05.08.2010 Agendia inaugurates new state-of-the-art clinical genomics laboratory in Irvine, CA more...

03.08.2010 Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering more...

15.07.2010 Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests more...

23.06.2010 Santaris Pharma A/S and miRagen Therapeutics, Inc. form strategic alliance to develop microRNA-targeted medicines for the treatment of cardiovascular disease
more...

15.06.2010 Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound more...

12.06.2010 Horizon Pharma, Inc. Announces Phase 3 Study of LODOTRA® Demonstrates 12-Month Sustained Efficacy in Rheumatoid Arthritis more...

09.06.2010 Horizon Pharma Announces LODOTRA® and HZT-501 Data to be Presented at the European League Against Rheumatism (EULAR) Annual Congress
more...

07.06.2010 Pieris AG Appoints Chief Scientific Officer more...

07.06.2010 Action Pharma obtains encouraging preliminary results in a phase II clinical trial with AP214 more...

04.06.2010 Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting more...

More news